Participant flow

A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors · Source last updated 2026-02-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   vobramitamab duocarmazine 2.0 mg/kg, IV, every 4 weeks

   id

   FG000

   title

   Part 1: MGC018 2.0 mg (Arm A)

2. description

   vobramitamab duocarmazine 2.7 mg/kg, IV, every 4 weeks

   id

   FG001

   title

   Part 1: MGC018 2.7 mg (Arm B)

3. description

   abiraterone 1000 mg once daily or enzalutamide 160 mg once daily.

   id

   FG002

   title

   Part 1: Control Arm

4. description

   vobramitamab duocarmazine 2.7 mg.kg, IV, every 4 weeks

   id

   FG003

   title

   Part 2

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         23

      2. group Id

         FG001

         num Subjects

         20

      3. group Id

         FG002

         num Subjects

         0

      4. group Id

         FG003

         num Subjects

         2

      type

      Death

   2. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         1

      3. group Id

         FG002

         num Subjects

         0

      4. group Id

         FG003

         num Subjects

         0

      type

      Lost to Follow-up

   3. reasons

      1. group Id

         FG000

         num Subjects

         9

      2. group Id

         FG001

         num Subjects

         13

      3. group Id

         FG002

         num Subjects

         4

      4. group Id

         FG003

         num Subjects

         0

      type

      Withdrawal by Subject

   4. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      3. group Id

         FG002

         num Subjects

         1

      4. group Id

         FG003

         num Subjects

         0

      type

      Elected to receive vobramitamab duocarmazine after protocol amendment 2.

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         91

      2. group Id

         FG001

         num Subjects

         90

      3. group Id

         FG002

         num Subjects

         7

      4. group Id

         FG003

         num Subjects

         4

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         91

      2. group Id

         FG001

         num Subjects

         90

      3. group Id

         FG002

         num Subjects

         7

      4. group Id

         FG003

         num Subjects

         4

      type

      Intent-to-treat Population

   3. achievements

      1. group Id

         FG000

         num Subjects

         90

      2. group Id

         FG001

         num Subjects

         86

      3. group Id

         FG002

         num Subjects

         3

      4. group Id

         FG003

         num Subjects

         4

      type

      Safety Population

   4. achievements

      1. group Id

         FG000

         num Subjects

         59

      2. group Id

         FG001

         num Subjects

         49

      3. group Id

         FG002

         num Subjects

         3

      4. group Id

         FG003

         num Subjects

         4

      type

      Tumor Response Evaluable Population

   5. achievements

      1. group Id

         FG000

         num Subjects

         83

      2. group Id

         FG001

         num Subjects

         71

      3. group Id

         FG002

         num Subjects

         0

      4. group Id

         FG003

         num Subjects

         0

      type

      Prostate-specific Antigen (PSA) Response Evaluable Population

   6. achievements

      1. group Id

         FG000

         num Subjects

         90

      2. group Id

         FG001

         num Subjects

         86

      3. group Id

         FG002

         num Subjects

         0

      4. group Id

         FG003

         num Subjects

         4

      type

      Anti-drug Antibody (ADA) Evaluable Population

   7. achievements

      1. group Id

         FG000

         num Subjects

         58

      2. group Id

         FG001

         num Subjects

         56

      3. group Id

         FG002

         num Subjects

         2

      4. group Id

         FG003

         num Subjects

         2

      type

      COMPLETED

   8. achievements

      1. group Id

         FG000

         num Subjects

         33

      2. group Id

         FG001

         num Subjects

         34

      3. group Id

         FG002

         num Subjects

         5

      4. group Id

         FG003

         num Subjects

         2

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice